Carole Diane Mitnick, Sc.D.
Co-Author
This page shows the publications co-authored by Carole Mitnick and Kwonjune Seung.
Connection Strength
4.017
-
Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis. Clin Infect Dis. 2020 07 11; 71(2):415-418.
Score: 0.883
-
Salvage therapy for multidrug-resistant tuberculosis. Clin Microbiol Infect. 2014 May; 20(5):441-6.
Score: 0.549
-
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings. Eur Respir J. 2022 01; 59(1).
Score: 0.246
-
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021 Sep 25; 22(1):651.
Score: 0.240
-
INCIDENCE OF HIGH GRADE QTCF PROLONGATION AND ITS MANAGEMENT AMONG PATIENTS UNDERGOING TREATMENT FOR DRUG RESISTANT TUBERCULOSIS (DR-TB): CASE SERIES. Afr J Infect Dis. 2021; 15(2 Suppl):38-41.
Score: 0.239
-
Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study. Am J Respir Crit Care Med. 2021 01 01; 203(1):111-119.
Score: 0.228
-
Introducing new and repurposed TB drugs: the endTB experience. Int J Tuberc Lung Dis. 2020 10 01; 24(10):1081-1086.
Score: 0.224
-
High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients. J Hepatol. 2020 05; 72(5):1028-1029.
Score: 0.216
-
The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens. BMC Infect Dis. 2019 Aug 20; 19(1):733.
Score: 0.208
-
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018 09 01; 198(5):657-666.
Score: 0.194
-
Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. BMC Infect Dis. 2016 08 27; 16(1):453.
Score: 0.169
-
Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One. 2013; 8(3):e58664.
Score: 0.133
-
Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008 Aug 07; 359(6):563-74.
Score: 0.097
-
Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea. Int J Tuberc Lung Dis. 2004 Mar; 8(3):361-8.
Score: 0.071
-
Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid and other second-line drugs. Clin Infect Dis. 2022 Mar 04.
Score: 0.062
-
Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort. Clin Infect Dis. 2022 Jan 13.
Score: 0.061
-
Setting up pharmacovigilance based on available endTB Project data for bedaquiline. Int J Tuberc Lung Dis. 2020 10 01; 24(10):1087-1094.
Score: 0.056
-
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018 09 08; 392(10150):821-834.
Score: 0.049
-
Surgery as an Adjunctive Treatment for Multidrug-Resistant Tuberculosis: An Individual Patient Data Metaanalysis. Clin Infect Dis. 2016 Apr 01; 62(7):887-895.
Score: 0.040
-
Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012; 9(8):e1001300.
Score: 0.032
-
Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB. Int J Tuberc Lung Dis. 2006 Mar; 10(3):290-6.
Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.